Exhibit # 1

BIOTRONIK

6024 SW Jean rd. Bldg. B
Lake Oswego, OR 97035
503-675-2187
503-699-2785 (fax)

October 8, 2002

FEDERAL COMMUNICATIONS COMMISSION
Experimental Radio Service
P.O. Box 358320
Pittsburgh, PA 15251-5320

Regarding FCC File # 0223-EX-PL-2002 [Reference Number 2265]

To the Experimental Licensing Branch,

Biotronik, Inc. seeks experimental licensing for use of the proposed Medical Implant Communications Service (MICS) band for medical device manufacturers to provide RF transmissions within this bandwidth for implantable life support products. Biotronik is a leading manufacturer of implantable pacemaker and defibrillator electronics, and wishes to initiate evaluation and development of RF communications from the implant to an external receiver.

Biotronik has designed a Colpitts oscillator transmitter, which will be integrated into pacemaker and defibrillator electronics products. This transmitter will provide critical patient data to a mobile receiver 2 to 3 meters from the source. The maximum output power of the transmitter will not exceed 25µWatts. This RF transmission will allow for critical results of a patient's heart condition to be presented to a physician without invasive interrogation.

Detailed Description of System Operation

Biotronik monitoring communications are provided in a series of distinct data transmission steps and electronic systems. A block diagram of the transmission path is shown below.



- Communication starts with the implant, which activates an RF transmitter at 403.65MHz +/- 75KHz carrier frequency. The bandwidth is 40KHz. The maximum deviation of the carrier is 40KHz + 150KHz = 190KHz. The transmitter circuitry is integrated within the pacemaker

electronics. Data is transmitted at a distance of two to three meters to a bedside receiver, which is interfaced to a telephone network.

- The patient is equipped with a receiver centered at 403.65MHz with a 300KHz bandwidth to accept the incoming data. The receiver is interfaced to a telephone network, which provides a means for transmission of data via telephone to the Biotronik service center. Specialized analysts at the Biotronik Service Center receive incoming data and generate a summarized report, which is forwarded to the physician.

Note: Each transmitter will have a unique serial number that will be transmitted as part of the data stream. This identifier can be used in the absence of a call sign for station identification (line item 14).

Scope of Experimentation

The experimental license is being sought to allow for a scientific study to be performed. The protocol for this study is based on prior approval of the Belos DR-T ICD by the Food and Drug Administration.

Biotronik plans to perform this study with a maximum of 300 experimental Belos DR-T implants under clinical evaluation. Each transmitter/receiver will provide less than or equal to 10 transmissions per day. The duration of each transmission is approximately 280 milliseconds. The entire study will have a duration of less than the 2 years allotted by the experimental license. A summary of the proposed scientific study is attached for your review.

The implanted units are obviously mobile, as is the receiver station. Sites for the study have yet to be determined, but will be in various clinical locations throughout the United States. The exact geographical coordinates during operation is presently unknown.

The experimental license application requests 400 units to be authorized. As defined above, 300 will be used for the scientific study, and the additional 100 units are requested for the purposes of research and development prototypes, validation units, and working demonstration systems for marketing purposes.

If there are any further questions regarding the specific objectives sought with this experimental license, please contact me at (503) 675-2187 or E-mail: maj@biotronikusa.com.

Sincerely,

Mark Johnson
Director, US Marketing
Biotronik, Inc.